Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m(2)) were defined: underweight <18 kg/m(2); normal 18-25 kg/m(2); overweight >25-30 kg/m(2); and obese >30 kg/m(2). Multivariable analysis referenced to the normal weight group showed an increased risk of death for underweight patients in the RD group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P = .002), but not in the URD group. There were no other differences in outcomes among the other weight groups within the other HCT groups. Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse outcomes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone should not be considered a barrier to HCT.
Navarro
Willis H
WH
National Marrow Donor Program, Minneapolis, Minnesota 55413, USA. wnavarro@nmdp.org
Agovi
Manza-A
MA
Logan
Brent R
BR
Ballen
Karen
K
Bolwell
Brian J
BJ
Frangoul
Haydar
H
Gupta
Vikas
V
Hahn
Theresa
T
Ho
Vincent T
VT
Juckett
Mark
M
Lazarus
Hillard M
HM
Litzow
Mark R
MR
Liesveld
Jane L
JL
Moreb
Jan S
JS
Marks
David I
DI
McCarthy
Philip L
PL
Pasquini
Marcelo C
MC
Rizzo
J Douglas
JD
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000706:statistics & numerical data*; D015897:Comorbidity; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000453:epidemiology*; D050177:Overweight / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D013851:Thinness / Q000453:epidemiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D019653:Myeloablative Agonists